GlassScriptPhysician profile
Robert T Campbell
NPI 1780325787
$2,882.82
in general payments reported to CMS, 2019-2025
27 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $408 · 2023: $566 · 2024: $1,623 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,249 · Food and Beverage: $1,218 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,249.10 |
| Food and Beverage | $1,217.77 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,444.71 | 2024 | Ams 700 Cxr Rte Kit, Jetstream Sc, Ams 700 |
| Lilly USA, LLC | $288.38 | 2022-2023 | Jardiance, Emgality, Mounjaro |
| Abbvie INC. | $271.92 | 2022-2025 | |
| Antares Pharma, INC. | $106.67 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Sanofi-Aventis U.S. LLC | $105.81 | 2022-2023 | |
| Innovation Technologies INC | $69.91 | 2025 | Irrisept |
| Dendreon Pharmaceuticals LLC | $51.53 | 2024-2025 | Provenge |
| Medtronic, INC. | $48.52 | 2025 | Altaviva |
| Biohaven Pharmaceutical Holding Company LTD. | $46.38 | 2022 | |
| Sumitomo Pharma America, INC. | $45.65 | 2023-2025 | Gemtesa |
| Hologic Sales and Service, LLC | $38.60 | 2024-2025 | Aptima |
| Halozyme INC | $36.44 | 2023 | |
| Idorsia Pharmaceuticals US INC | $36.35 | 2023 | Quviviq |
| Novo Nordisk INC | $30.39 | 2023 | |
| Endo USA, INC. | $29.23 | 2025 | Xiaflex |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $29.07 | 2024 | Prolaris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.44 | 2022-2023 | Xifaxan |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.11 | 2025 | Rexulti |
| Impel Pharmaceuticals INC. | $20.16 | 2023 | Trudhesa |
| Laborie Medical Technologies Corp. | $19.98 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Ironwood Pharmaceuticals, INC | $19.69 | 2023 | Linzess |
| Shield Therapeutics INC | $17.37 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $17.22 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.33 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $13.65 | 2023 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.